QuikClot Combat Gauze (#Z MED)
Z-Medica Corporation, focused on innovative blood clotting nano-technologies, announced that the United States Department of Defense has selected the company's newest hemostatic product, QuikClot Combat Gauze brand, for all military services as the first-line hemostatic treatment for life-threatening hemorrhage that is not amenable to tourniquet placement. Bleeding is the number one cause of death for soldiers injured in battle and QuikClot products offer the most effective solution to severe blood loss outside the operating room setting. They have been proven in battlefield use and, with more than one million units deployed, are the leading hemostatic agents in the field.
The Committee on Tactical Combat Casualty Care (CoTCCC) made the decision to recommend QuikClot Combat Gauze after reviewing test reports on a number of hemostatic products. QuikClot Combat Gauze was the only one of these products tested by both the Naval Medical Research Center and the U.S. Army Institute for Surgical Research. In addition to test efficacy, the committee sited a number of other factors in according QuikClot Combat Gauze the number one position:
Preference for the gauze delivery format, which is familiar to combat medical personnel. Ability of QuikClot Combat Gauze to be shaped to any wound and to reach bleeding vessels in penetrating wounds. Ease of removal once hemostasis has been achieved.
With QuikClot Combat Gauze we have provided a product that is virtually 100% effective in a very intuitive format that can be applied quickly and simply by anyone.
QuikClot Combat Gauze combines surgical gauze with a proprietary inorganic material that stops arterial and venous bleeding in seconds -- even more rapidly in this format than earlier Z-Medica products. Based on a different mineral than zeolite-based QuikClot products, it generates no heat. It shares the benefit of being inert and non-allergenic. QuikClot Combat Gauze comes in rolls four yards long by three inches wide.
In addition to the military testing, the new product was tested in pre-clinical trials at the University of California, Santa Barbara, the University of Massachusetts Medical School and at various field facilities.